Published in Heart Disease Weekly, September 3rd, 2006
The report was published in the Summer 2006 issue of Preventive Cardiology.
The paper proposes that clinical laboratories set greater than or equal to 235 ng/mL (the median value of the samples analyzed in this study) as the Lp-PLA2 concentration decision value to be used to decide whether patients should be moved to a higher cardiovascular risk category. This cut point is not proposed as a treatment...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.